Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Large Increase in Short Interest
by Amy Steele · The Cerbat GemDaiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 191,579 shares, a growth of 1,183.6% from the June 30th total of 14,925 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 394,403 shares, the short-interest ratio is presently 0.5 days.
Analyst Ratings Changes
Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Daiichi Sankyo has an average rating of “Hold”.
View Our Latest Report on DSNKY
Daiichi Sankyo Trading Up 1.4%
Shares of Daiichi Sankyo stock opened at $17.25 on Friday. Daiichi Sankyo has a 12-month low of $14.98 and a 12-month high of $27.50. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average is $16.42 and its 200-day moving average is $17.91. The stock has a market cap of $32.13 billion, a P/E ratio of 18.35, a P/E/G ratio of 2.98 and a beta of -0.17.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. The firm had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Equities research analysts predict that Daiichi Sankyo will post 0.96 earnings per share for the current fiscal year.
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.